Physician profile
Aashoo Mentreddi
NPI 1215226725
$175,788.57
in general payments reported to CMS, 2019-2025
63 companies · $5,893 in 2025
The $5,893 reported for 2025 was more than what 86% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64K · 2020: $23K · 2021: $26K · 2022: $12K · 2023: $33K · 2024: $11K · 2025: $5,893.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $41K · Food and Beverage: $5,685 · Travel and Lodging: $3,597.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $40,675.50 |
| Food and Beverage | $5,684.73 |
| Travel and Lodging | $3,597.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acorda Therapeutics, INC | $89,453.42 | 2019-2024 | Inbrija |
| Abbvie INC. | $68,151.78 | 2019-2025 | |
| Merz Pharmaceuticals, LLC | $5,741.78 | 2022-2025 | Inbrija, Xeomin |
| Sunovion Pharmaceuticals INC. | $3,592.40 | 2020-2022 | |
| Acadia Pharmaceuticals INC | $1,817.86 | 2019-2025 | Nuplazid, Daybue |
| Boston Scientific Corporation | $717.67 | 2019-2025 | Vercise, General - Dbs |
| Ucb, INC. | $599.61 | 2019-2024 | Briviact, Fintepla, Rystiggo |
| Abbott Laboratories | $476.92 | 2019-2024 | Infinity |
| Medtronic USA, INC. | $333.31 | 2019 | |
| Novartis Pharmaceuticals Corporation | $275.82 | 2019-2025 | |
| Pfizer INC. | $264.10 | 2022-2025 | |
| Eisai INC. | $246.32 | 2020-2025 | |
| Neurocrine Biosciences, INC. | $244.71 | 2019-2025 | Ingrezza, Ongentys |
| Argenx US, INC. | $234.89 | 2022-2024 | Vyvgart Hytrulo, Vyvgart |
| Lilly USA, LLC | $229.67 | 2019-2024 | Amyvid, Reyvow, Emgality |
Show all 61 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aashoo Mentreddi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.